EVIDENCE-BASED CHOICE OF ACE INHIBITORS
Angiotensin-converting enzyme (ACE) inhibitors are currently one of the most frequently used groups of cardiovascular medications. In addition to wellknown indications, such as arterial hypertension (AH), chronic heart failure (CHF), and Type 2 diabetes mellitus (DM-2), some ACE inhibitors could be...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2012-08-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1256 |
| _version_ | 1826561469842456576 |
|---|---|
| author | G. E. Gendlin O. A. Miller A. V. Melekhov |
| author_facet | G. E. Gendlin O. A. Miller A. V. Melekhov |
| author_sort | G. E. Gendlin |
| collection | DOAJ |
| description | Angiotensin-converting enzyme (ACE) inhibitors are currently one of the most frequently used groups of cardiovascular medications. In addition to wellknown indications, such as arterial hypertension (AH), chronic heart failure (CHF), and Type 2 diabetes mellitus (DM-2), some ACE inhibitors could be used in other clinical situations. The medications with additional vascular activity (for example, perindopril A) have certain benefits, compared to other ACE inhibitors. |
| first_indexed | 2024-04-09T20:51:41Z |
| format | Article |
| id | doaj.art-0dd19e7bcfe549c78a334127501cbb28 |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2025-03-14T09:32:41Z |
| publishDate | 2012-08-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-0dd19e7bcfe549c78a334127501cbb282025-03-02T11:42:30Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202012-08-010487921055EVIDENCE-BASED CHOICE OF ACE INHIBITORSG. E. Gendlin0O. A. Miller1A. V. Melekhov2Russian Medical University, MoscowRussian Medical University, MoscowRussian Medical University, MoscowAngiotensin-converting enzyme (ACE) inhibitors are currently one of the most frequently used groups of cardiovascular medications. In addition to wellknown indications, such as arterial hypertension (AH), chronic heart failure (CHF), and Type 2 diabetes mellitus (DM-2), some ACE inhibitors could be used in other clinical situations. The medications with additional vascular activity (for example, perindopril A) have certain benefits, compared to other ACE inhibitors.https://russjcardiol.elpub.ru/jour/article/view/1256new indications for ace inhibitorsendothelial dysfunctionvasoprotectionperindopril aprimary prevention of coronary heart diseasesecondary prevention of stroke |
| spellingShingle | G. E. Gendlin O. A. Miller A. V. Melekhov EVIDENCE-BASED CHOICE OF ACE INHIBITORS Российский кардиологический журнал new indications for ace inhibitors endothelial dysfunction vasoprotection perindopril a primary prevention of coronary heart disease secondary prevention of stroke |
| title | EVIDENCE-BASED CHOICE OF ACE INHIBITORS |
| title_full | EVIDENCE-BASED CHOICE OF ACE INHIBITORS |
| title_fullStr | EVIDENCE-BASED CHOICE OF ACE INHIBITORS |
| title_full_unstemmed | EVIDENCE-BASED CHOICE OF ACE INHIBITORS |
| title_short | EVIDENCE-BASED CHOICE OF ACE INHIBITORS |
| title_sort | evidence based choice of ace inhibitors |
| topic | new indications for ace inhibitors endothelial dysfunction vasoprotection perindopril a primary prevention of coronary heart disease secondary prevention of stroke |
| url | https://russjcardiol.elpub.ru/jour/article/view/1256 |
| work_keys_str_mv | AT gegendlin evidencebasedchoiceofaceinhibitors AT oamiller evidencebasedchoiceofaceinhibitors AT avmelekhov evidencebasedchoiceofaceinhibitors |